Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE), parent of health and longevity brand IM8, appointed Brian J. Rosin as U.S. Chief Financial Officer on May 14, 2026. He will lead finance, capital allocation, investor relations support, and financial infrastructure, reporting to CEO Danny Yeung.
Rosin brings nearly 20 years of experience in consumer e-commerce and premium wellness subscriptions. IM8 is active in 40+ countries and is projecting $190–$210 million in 2026 revenue, its second year from launch.
Prenetics (NASDAQ: PRE) reported preliminary Q1 2026 revenue of $36.0M, up 334.5% year-over-year, with IM8 contributing $33.8M (nearly 6x YoY). Gross profit was $23.3M, with a loss from operations of $8.9M and adjusted EBITDA loss of $5.6M.
The company raised 2026 IM8 revenue guidance to $190M–$210M and projects Q2 2026 revenue of $46M–$48M. Prenetics sold digital assets for $41.3M, executed $19M of a $40M buyback, and reports debt-free liquidity of about $147M.
Prenetics (NASDAQ: PRE) will report first-quarter 2026 financial results for the period ended March 31, 2026, before market open on May 14, 2026. The company will host an earnings conference call and webcast the same day.
Conference call details: Thursday, May 14, 2026; Time: 8:30 a.m. Eastern Time; Dial-in: 1-877-425-9470; International: 1-201-389-0878; Webcast: PRE Conference Call. An audio replay will be available on the company's investor relations website.
Prenetics (NASDAQ: PRE) announced a multi-year partnership making IM8 the exclusive Official Health Supplements Partner of Inter Miami CF, including an equity stake by the club. IM8 products will be integrated into Inter Miami’s training center and available to players, plus stadium and global brand activations.
IM8 reported surpassing $100M ARR within 11 months and projects $180–200M revenue for full-year 2026; the deal includes NIL rights for a minimum of four players and international usage across IM8’s 40+ country footprint.
Prenetics (NASDAQ: PRE) announced that IM8 Health has partnered with Vitamin Angels to address global malnutrition, committing to impact 400,000 pregnant women, infants, and children under five in year one. Vitamin Angels reaches over 74 million people annually and holds a four-star Charity Navigator rating.
The partnership leverages IM8’s presence in 31 countries and Vitamin Angels’ 31-year delivery network, with a long-term ambition to scale to millions of lives through sustained funding and awareness.
Prenetics (NASDAQ: PRE) announced a multi-year global partnership making NBA champion Giannis Antetokounmpo a Global Partner and shareholder in IM8. IM8 reached $100M ARR in 11 months, delivered 22M servings, recorded 750,000 purchases across 31 countries, and expects $180–200M revenue in 2026. Prenetics reports ~$160M liquidity, zero debt, a $40M repurchase program, and adjusted EBITDA profitability targeted by Q4 2027. IM8 products are NSF Certified for Sport and supported by a 12-week randomized controlled trial.
Prenetics (NASDAQ: PRE) announced a strategic partnership between its IM8 brand and Superpower on March 24, 2026 to integrate clinical-grade supplementation with comprehensive blood diagnostics.
The deal offers IM8 90-day subscribers a $49 Superpower membership (75% off the $199 price), monthly subscribers a $99 rate, access to 100+ biomarker testing, Quest availability at >2,000 locations, and IM8 products featured in Superpower's personalized protocols.
Prenetics (NASDAQ: PRE) will attend the 38th Annual ROTH Conference in Laguna Niguel, CA, March 22–24, 2026. Management will hold one-on-one investor meetings and participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel at 12:00 p.m. PT on Monday, March 23, 2026. Both sessions will be available via webcast on the company’s investor relations website. To schedule meetings, investors should contact Investor Relations or their ROTH representative.
Prenetics (NASDAQ: PRE) authorized a $40.0 million share repurchase program over 12 months, bringing total insider and board-backed commitment to $42.75 million. The company reports $164 million in total adjusted liquidity, zero debt, and IM8 guidance of $180–200 million revenue for 2026, targeting adjusted EBITDA profitability by Q4 2027. Management purchased ~$2.75 million of stock in recent post-earnings windows. The program allows open market, negotiated and Rule 10b5-1 purchases and may be modified or suspended at any time.
Prenetics (NASDAQ: PRE) executives executed a second consecutive round of post-earnings open market purchases during Feb 23–27, 2026. The leadership team bought 76,060 shares for approximately $1.301 million at an average price of ~$17.11 per share.
Combined with prior purchases in November 2025, executives have personally invested about $2.75 million across two post-earnings windows. CEO Danny Yeung purchased 42,282 shares for ~$750,000 (~$17.71/share) in this round; other officers also made purchases. Management said the IM8 business is performing and the share price does not yet reflect that progress.